Jazz Pharmaceuticals plc

NASDAQ:JAZZ  
140.71
+3.50 (+2.55%)
Products

Jazz Pharmaceuticals Announces FDA Approval Of Additional Indication For Vyxeos

Published: 03/30/2021 22:25 GMT
Jazz Pharmaceuticals plc (JAZZ) - Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and Cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients.